Evolus reports Q3 EPS (30c), consensus (10c) | Nasdaq

Q: How much money does Evolus make a year?

Evolus (NASDAQ:EOLS) has a recorded annual revenue of $148.62 million. How much profit does Evolus generate each year? Evolus (NASDAQ:EOLS) has a recorded net income of -$74.41 million. EOLS has generated -$1.11 earnings per share over the last four quarters. What is Evolus's EPS forecast for next year?

Sep 13, 2024 · Evolus reports Q3 EPS (30c), consensus (10c) November 06, 2024 — 04:24 pm EST Written by TheFly for TipRanks ->

$61
OFF

Evolus Reports Q3 EPS (30c), Consensus (10c) | Markets Insider

1 week from now

Nov 6, 2024 · Evolus reports Q3 EPS (30c), consensus (10c) TipRanks. Nov. 6, 2024, 03:24 PM. Reports Q3 revenue $61.1M, consensus $62.2M. “Our third quarter results underscore the …

businessinsider.com

$260
OFF

Analysts Offer Insights On Healthcare Companies: Evolus (EOLS ...

1 week from now

Dec 16, 2024 · Evolus, Inc. Reports Strong Q3 2024 Growth; Evolus reports Q3 EPS (30c), consensus (10c) Evolus sees FY24 revenue $260M-$266M, consensus $266.1M; Evolus says …

businessinsider.com

$260
OFF

Evolus Maintains Strong Growth Outlook Despite Earnings Miss: A …

1 week from now

Nov 7, 2024 · Evolus, Inc. Reports Strong Q3 2024 Growth; Evolus reports Q3 EPS (30c), consensus (10c) Evolus sees FY24 revenue $260M-$266M, consensus $266.1M; Evolus says …

businessinsider.com

50%
OFF

Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates

1 week from now

Nov 6, 2024 · Evolus (EOLS) delivered earnings and revenue surprises of -137.50% and 2.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies …

yahoo.com

$61
OFF

Evolus Reports Q3 EPS (30c), Consensus (10c) EOLS - The Fly

1 week from now

Nov 6, 2024 · Reports Q3 revenue $61.1M... EOLS Login | Join Sign In with: Google LinkedIn ... Evolus reports Q3 EPS (30c), consensus (10c) 06. Nov. 11. Mar. Available to The Fly …

thefly.com

22%
OFF

Evolus Reports Third Quarter 2024 Results - FT.com

1 week from now

Nov 6, 2024 · Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33%; Received Approval for Estyme ® Injectable Hyaluronic Acid (HA) Gels in …

ft.com

$2400
OFF

7855 Boulevard East Unit Parker Imperial - Apartments.com

1 week from now

See Condo Parker Imperial for rent at 7855 Boulevard East in North Bergen, NJ from $2400 plus find other available North Bergen condos. Apartments.com has 3D tours, HD videos, reviews …

apartments.com

0%
OFF

North Bergen, New-jersey Zoning Map | Zoning Reports - Zoneomics

1 week from now

May 2, 2024 · Buy report Download Sample Report. Zoning for North Bergen, NJ Largest Zones in North Bergen, NJ. 1,096.53 sq. m 749.7 sq. m 458.01 sq. m 420.23 sq. m 360.74 sq. m 0% …

zoneomics.com

1%
OFF

Wipro Reports Q3 EPS 4c, Consensus 3c - Markets Insider

1 week from now

1 day ago · Reports Q3 revenue $2.61B, an an increase of 0.1% QoQ and 0.5% YoY. Srini Pallia, CEO and Managing Director, said “In a seasonally weak quarter, our strong in quarter …

businessinsider.com

22%
OFF

Evolus Reports Third Quarter 2024 Results - Morningstar

1 week from now

Nov 6, 2024 · Evolus Reports Third Quarter 2024 Results. Total Net Revenue of $61.1 Million for Q3 2024, Up 22% from Q3 2023; Year-To-Date Growth of 33% ... About Evolus, Inc. Evolus …

morningstar.com

$23.78
OFF

Telos Reports Q3 EPS (10c), Consensus (14c) - Nasdaq

1 week from now

Nov 12, 2024 · Reports Q3 revenue $23.783M, consensus $22.99M. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

nasdaq.com

FAQs about Evolus reports Q3 EPS (30c), consensus (10c) | Nasdaq Coupon?

Should you buy Evolus stock after Q3 earnings?

Unfortunately, although Evolus stock enjoyed a strong bull run between June and early November last year, with shares reaching a high of $17 per share, a market cap valuation of roughly just under $1bn, it then began to tumble in value after Evolus released a weak set of Q3 earnings. At first, the results and updates appear quite positive. ...

When is Evolus's next earnings date?

Evolus has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 13th, 2024 based off prior year's report dates. When is Evolus's earnings date? ...

Should you buy Evolus (EOLs – research report)?

Evolus (EOLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Serge Belanger from Needham maintained a Buy rating on the stock and has a $22.00 price target. ...

How much will Evolus make in 2023?

Outlook Evolus narrows its full year total net revenue guidance to $260 million to $266 million, representing year-over-year growth of 29% to 32% from 2023 results and well above the estimated growth rate of the aesthetic neurotoxin market. ...

Is Evolus a profitable stock?

Full-year revenue guidance was “narrowed” to $260m - $266m — an annual uplift of 29% - 32% — and stated it would be profitable on a non-GAAP basis in Q4 2024, and in full-year 2025, and finally, that it: Despite the generally positive nature of these updates, Evolus stock slipped <$12 per share by the middle of November. ...

How much money does Evolus make a year?

Evolus (NASDAQ:EOLS) has a recorded annual revenue of $148.62 million. How much profit does Evolus generate each year? Evolus (NASDAQ:EOLS) has a recorded net income of -$74.41 million. EOLS has generated -$1.11 earnings per share over the last four quarters. What is Evolus's EPS forecast for next year? ...